The California State Teachers Retirement System invests in 26,607 by purchasing CytomX Therapeutics Inc. (CTMX) shares

The California State Teachers Retirement System invests in 26,607 by purchasing CytomX Therapeutics Inc. (CTMX) shares

California State Teachers Retirement System increased its stake in CytomX Therapeutics Inc. (NASDAQ:CTMX) by 164.0% during the second quarter, Holdings Channel reports. The institutional investor owned 42,830 shares of the company’s stock after buying an additional 26,607 shares during the period. California State Teachers Retirement System owned approximately 0.12% of CytomX Therapeutics worth $438,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. State Street Corp raised its position in CytomX Therapeutics by 34.8% in the first quarter. State Street Corp now owns 91,777 shares of the company’s stock valued at $1,182,000 after buying an additional 23,698 shares in the last quarter. Geode Capital Management LLC raised its position in CytomX Therapeutics by 17.5% in the first quarter. Geode Capital Management LLC now owns 68,254 shares of the company’s stock valued at $880,000 after buying an additional 10,184 shares in the last quarter. Spark Investment Management LLC bought a new position in CytomX Therapeutics during the first quarter valued at about $398,000. BlackRock Institutional Trust Company N.A. raised its position in CytomX Therapeutics by 78.5% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 57,918 shares of the company’s stock valued at $747,000 after buying an additional 25,477 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its position in CytomX Therapeutics by 208.4% in the second quarter. Bank of New York Mellon Corp now owns 71,738 shares of the company’s stock valued at $733,000 after buying an additional 48,474 shares in the last quarter. Institutional investors and hedge funds own 51.95% of the company’s stock.

CytomX Therapeutics Inc. (NASDAQ:CTMX) traded down 4.22% on Wednesday, reaching $13.83. The company’s stock had a trading volume of 58,278 shares. The company’s market cap is $501.86 million. CytomX Therapeutics Inc. has a 12 month low of $9.01 and a 12 month high of $24.68. The stock’s 50 day moving average price is $14.25 and its 200 day moving average price is $11.96.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings results on Wednesday, August 3rd. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.02. CytomX Therapeutics had a negative net margin of 579.42% and a negative return on equity of 91.59%. Equities research analysts forecast that CytomX Therapeutics Inc. will post ($1.59) earnings per share for the current year.

Separately, Zacks Investment Research lowered CytomX Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, July 6th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. CytomX Therapeutics presently has an average rating of “Buy” and an average target price of $19.00.

About CytomX Therapeutics

CytomX Therapeutics, Inc is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets.

Related posts

Leave a Comment